S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
Log in
NASDAQ:AMGN

Amgen Competitors

$245.49
+3.83 (+1.58 %)
(As of 01/15/2021 08:00 PM ET)
Add
Compare
Today's Range
$240.00
Now: $245.49
$246.80
50-Day Range
$220.99
MA: $229.04
$241.66
52-Week Range
$177.05
Now: $245.49
$264.97
Volume176,840 shs
Average Volume2.06 million shs
Market Capitalization$142.92 billion
P/E Ratio19.80
Dividend Yield2.61%
Beta0.76

Competitors

Amgen (NASDAQ:AMGN) Vs. GILD, VRTX, REGN, BIIB, ALXN, and SGEN

Should you be buying AMGN stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Amgen, including Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), and Seagen (SGEN).

Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Volatility and Risk

Gilead Sciences has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Gilead Sciences and Amgen, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences2151102.32
Amgen1121702.53

Gilead Sciences presently has a consensus price target of $93.8276, indicating a potential upside of 48.16%. Amgen has a consensus price target of $255.52, indicating a potential upside of 4.09%. Given Gilead Sciences' higher probable upside, equities research analysts plainly believe Gilead Sciences is more favorable than Amgen.

Earnings & Valuation

This table compares Gilead Sciences and Amgen's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion3.54$5.39 billion$6.1410.31
Amgen$23.36 billion6.12$7.84 billion$14.8216.56

Amgen has higher revenue and earnings than Gilead Sciences. Gilead Sciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Gilead Sciences and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences5.48%37.77%12.76%
Amgen29.42%95.55%15.52%

Dividends

Gilead Sciences pays an annual dividend of $2.72 per share and has a dividend yield of 4.3%. Amgen pays an annual dividend of $6.40 per share and has a dividend yield of 2.6%. Gilead Sciences pays out 44.3% of its earnings in the form of a dividend. Amgen pays out 43.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amgen has raised its dividend for 1 consecutive years.

Insider and Institutional Ownership

76.4% of Gilead Sciences shares are held by institutional investors. Comparatively, 75.2% of Amgen shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by company insiders. Comparatively, 0.4% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Amgen beats Gilead Sciences on 13 of the 17 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Volatility & Risk

Vertex Pharmaceuticals has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Vertex Pharmaceuticals and Amgen, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals062312.83
Amgen1121702.53

Vertex Pharmaceuticals presently has a consensus price target of $289.6552, indicating a potential upside of 28.42%. Amgen has a consensus price target of $255.52, indicating a potential upside of 4.09%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Vertex Pharmaceuticals is more favorable than Amgen.

Earnings & Valuation

This table compares Vertex Pharmaceuticals and Amgen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion14.09$1.18 billion$4.2952.58
Amgen$23.36 billion6.12$7.84 billion$14.8216.56

Amgen has higher revenue and earnings than Vertex Pharmaceuticals. Amgen is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Vertex Pharmaceuticals and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals38.51%28.55%20.68%
Amgen29.42%95.55%15.52%

Institutional & Insider Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 75.2% of Amgen shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 0.4% of Amgen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Vertex Pharmaceuticals beats Amgen on 11 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Institutional & Insider Ownership

85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 75.2% of Amgen shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 0.4% of Amgen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Regeneron Pharmaceuticals has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.

Earnings & Valuation

This table compares Regeneron Pharmaceuticals and Amgen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion7.03$2.12 billion$21.4724.12
Amgen$23.36 billion6.12$7.84 billion$14.8216.56

Amgen has higher revenue and earnings than Regeneron Pharmaceuticals. Amgen is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Regeneron Pharmaceuticals and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals38.28%28.97%20.11%
Amgen29.42%95.55%15.52%

Analyst Recommendations

This is a summary of recent ratings and price targets for Regeneron Pharmaceuticals and Amgen, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals081612.72
Amgen1121702.53

Regeneron Pharmaceuticals presently has a consensus price target of $618.3929, indicating a potential upside of 19.40%. Amgen has a consensus price target of $255.52, indicating a potential upside of 4.09%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Regeneron Pharmaceuticals is more favorable than Amgen.

Summary

Regeneron Pharmaceuticals beats Amgen on 9 of the 15 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Institutional and Insider Ownership

83.5% of Biogen shares are owned by institutional investors. Comparatively, 75.2% of Amgen shares are owned by institutional investors. 0.5% of Biogen shares are owned by insiders. Comparatively, 0.4% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Biogen has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.

Valuation & Earnings

This table compares Biogen and Amgen's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$14.38 billion2.95$5.89 billion$33.578.22
Amgen$23.36 billion6.12$7.84 billion$14.8216.56

Amgen has higher revenue and earnings than Biogen. Biogen is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Biogen and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biogen35.63%51.00%23.54%
Amgen29.42%95.55%15.52%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Biogen and Amgen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biogen5151302.24
Amgen1121702.53

Biogen currently has a consensus price target of $306.1290, indicating a potential upside of 10.98%. Amgen has a consensus price target of $255.52, indicating a potential upside of 4.09%. Given Biogen's higher probable upside, analysts clearly believe Biogen is more favorable than Amgen.

Summary

Amgen beats Biogen on 8 of the 14 factors compared between the two stocks.

Alexion Pharmaceuticals (NASDAQ:ALXN) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Institutional and Insider Ownership

87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.2% of Amgen shares are owned by institutional investors. 4.0% of Alexion Pharmaceuticals shares are owned by insiders. Comparatively, 0.4% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Alexion Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.

Valuation & Earnings

This table compares Alexion Pharmaceuticals and Amgen's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alexion Pharmaceuticals$4.99 billion6.87$2.40 billion$9.7416.09
Amgen$23.36 billion6.12$7.84 billion$14.8216.56

Amgen has higher revenue and earnings than Alexion Pharmaceuticals. Alexion Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Alexion Pharmaceuticals and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alexion Pharmaceuticals16.32%23.16%14.76%
Amgen29.42%95.55%15.52%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Alexion Pharmaceuticals and Amgen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alexion Pharmaceuticals0161012.44
Amgen1121702.53

Alexion Pharmaceuticals currently has a consensus price target of $152.9615, indicating a potential downside of 2.39%. Amgen has a consensus price target of $255.52, indicating a potential upside of 4.09%. Given Amgen's stronger consensus rating and higher probable upside, analysts clearly believe Amgen is more favorable than Alexion Pharmaceuticals.

Summary

Amgen beats Alexion Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Seagen (NASDAQ:SGEN) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Institutional and Insider Ownership

87.2% of Seagen shares are owned by institutional investors. Comparatively, 75.2% of Amgen shares are owned by institutional investors. 31.1% of Seagen shares are owned by insiders. Comparatively, 0.4% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Seagen has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.

Valuation & Earnings

This table compares Seagen and Amgen's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seagen$916.71 million36.66$-158,650,000.00($1.33)-139.66
Amgen$23.36 billion6.12$7.84 billion$14.8216.56

Amgen has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Seagen and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Seagen25.34%20.46%16.67%
Amgen29.42%95.55%15.52%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Seagen and Amgen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seagen141112.71
Amgen1121702.53

Seagen currently has a consensus price target of $185.5714, indicating a potential downside of 0.10%. Amgen has a consensus price target of $255.52, indicating a potential upside of 4.09%. Given Amgen's higher probable upside, analysts clearly believe Amgen is more favorable than Seagen.

Summary

Seagen beats Amgen on 8 of the 15 factors compared between the two stocks.


Amgen Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Gilead Sciences logo
GILD
Gilead Sciences
2.7$63.33+1.5%$79.39 billion$22.45 billion65.29Decrease in Short Interest
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.4$225.55+0.3%$58.65 billion$4.16 billion28.48Increase in Short Interest
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.4$517.93+0.0%$54.62 billion$7.86 billion18.93
Biogen logo
BIIB
Biogen
2.1$275.84+1.6%$42.45 billion$14.38 billion9.13
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.8$156.70+0.0%$34.29 billion$4.99 billion36.61Decrease in Short Interest
Seagen logo
SGEN
Seagen
1.3$185.75+5.3%$31.96 billion$916.71 million73.13
Exact Sciences logo
EXAS
Exact Sciences
1.6$145.97+0.9%$21.87 billion$876.29 million-66.05
Incyte logo
INCY
Incyte
1.9$90.56+1.6%$20.31 billion$2.16 billion-57.68
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.6$166.36+0.8%$19.33 billion$219.75 million-21.25
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$82.97+1.9%$15.06 billion$1.70 billion18.99
Repligen logo
RGEN
Repligen
1.5$215.47+1.5%$10.94 billion$270.24 million262.77
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.1$107.69+1.5%$10.10 billion$788.10 million115.80
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.0$61.28+0.1%$8.57 billion$1.12 billion127.67
Novavax logo
NVAX
Novavax
1.6$127.43+2.0%$8.03 billion$18.66 million-24.41Decrease in Short Interest
Exelixis logo
EXEL
Exelixis
1.9$23.73+0.2%$7.56 billion$967.78 million49.44
United Therapeutics logo
UTHR
United Therapeutics
1.3$172.82+3.2%$7.20 billion$1.45 billion16.35Heavy News Reporting
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$47.43+0.8%$6.10 billion$195.99 million296.44Analyst Revision
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.2$21.84+6.6%$5.99 billion$182.24 million-18.99
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.5$106.29+0.3%$5.63 billion$1.11 billion34.18
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$80.50+0.1%$4.68 billion$806.43 million-11.40
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$62.02+2.2%$4.29 billion$36.13 million-92.57
Alkermes logo
ALKS
Alkermes
1.2$22.37+1.7%$3.56 billion$1.17 billion-48.63
OPKO Health logo
OPK
OPKO Health
1.9$4.55+0.7%$2.97 billion$901.90 million-25.28
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.1$15.75+2.8%$2.19 billion$102.43 million-26.25
Myriad Genetics logo
MYGN
Myriad Genetics
1.1$26.71+3.4%$1.87 billion$638.60 million-10.27
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$123.34+0.9%$1.79 billion$120.28 million-124.59
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.3$11.03+2.7%$1.77 billion$428.41 million15.99
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.9$109.04+4.5%$1.74 billionN/A-9.85Heavy News Reporting
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$8.80+2.4%$1.55 billion$48.83 million-11.58
Codexis logo
CDXS
Codexis
1.1$25.30+1.4%$1.50 billion$68.46 million-72.29
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.21+5.1%$1.42 billion$82.27 million-17.59
Innoviva logo
INVA
Innoviva
1.1$12.72+1.2%$1.24 billion$261.02 million6.49
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.9$27.45+6.5%$905.63 million$252 million-2.81
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$6.87+17.2%$832.53 million$322.07 million-6.54Increase in Short Interest
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.7$13.73+1.8%$765.68 million$227.19 million38.14
Curis logo
CRIS
Curis
0.9$12.80+7.9%$752.86 million$10 million-15.61
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.51+0.0%$752.16 million$150,000.00-5.01
MannKind logo
MNKD
MannKind
1.2$3.14+7.6%$735.02 million$63.04 million-14.95
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.6$17.53+2.6%$693.61 million$3.57 million-7.86
Agenus logo
AGEN
Agenus
1.6$3.35+2.1%$637 million$150.05 million-3.07
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.76+1.3%$633.68 million$59.29 million-25.06Analyst Revision
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$5.13+0.2%$560.78 million$35.22 million-3.74
Molecular Templates logo
MTEM
Molecular Templates
2.0$11.05+0.4%$552.10 million$22.27 million-5.42Decrease in Short Interest
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.59+5.6%$535.53 million$109.33 million-2.64
Geron logo
GERN
Geron
1.4$1.65+2.7%$502.96 million$460,000.00-4.71
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.58+6.8%$492.82 million$143.01 million-1.06
XOMA logo
XOMA
XOMA
1.4$39.93+0.1%$440.11 million$18.37 million-35.97Decrease in Short Interest
Verastem logo
VSTM
Verastem
1.8$2.45+1.2%$415.95 million$17.46 million-1.74
Fortress Biotech logo
FBIO
Fortress Biotech
1.3$3.37+6.2%$315.78 million$36.63 million-3.96Analyst Downgrade
Increase in Short Interest
PDL BioPharma logo
PDLI
PDL BioPharma
1.1$2.47+0.0%$282.15 million$54.76 million-2.19
This page was last updated on 1/19/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.